Kathryn e. Falberg

Filings by Kathryn e. Falberg span 5 companies, the busiest being Trade Desk, Inc., Arcus Biosciences, Inc. and Halozyme Therapeutics, Inc. We count 25 filings; the first trade dates from 13 January 2016 and the latest from 11 June 2026.

On the open market, the record shows 1 purchase worth €135k and 3 sales worth €23.7M. On balance, insiders were net sellers of €23.6M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 15 share grants and 2 option exercises. Since January 2026: no purchases and 1 sale on the market.

Most recently, on 12 June 2026, the filings show a share grant in Arcus Biosciences, Inc. The latest purchase dates back some time: it was published 1,413 days ago, on 5 December 2022. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.